Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 8;20(1):e0311900.
doi: 10.1371/journal.pone.0311900. eCollection 2025.

An implementation trial to mAnage siCkle CELl disEase through incReased AdopTion of hydroxyurEa in Nigeria (ACCELERATE): Study protocol

Emmanuel Peprah  1 , Joyce Gyamfi  1 , John Patena  1 , Hazal Kayalioglu  1 , Tania Hameed  1 , Gbenga Ogedegbe  2 , Hyungrok Do  3 , Dike Ojji  4 , Deborah Adenikinju  1 , Tayo Ajaye Oba  5   6 , Maxwell Nwegbu  5   6 , Hezekiah Isa  5   6 , Grace Shedul  7 , Alayo Y Sopekan  8 , Obiageli E Nnodu  5   6
Affiliations

An implementation trial to mAnage siCkle CELl disEase through incReased AdopTion of hydroxyurEa in Nigeria (ACCELERATE): Study protocol

Emmanuel Peprah et al. PLoS One. .

Abstract

Background: Despite the proven efficacy of evidence-based healthcare interventions in reducing adverse outcomes and mortality associated with Sickle Cell Disease (SCD), a vast majority of affected individuals in Africa remain deprived of such care. Hydroxyurea (HU) utilization among SCD patients in Sub-Saharan Africa (SSA) stands at less than 1%, while in Nigeria, approximately 13% of patients benefit from HU therapy. To enhance HU utilization, targeted implementation strategies addressing provider-level barriers are imperative. Existing evidence underscores the significance of addressing barriers such as inadequate healthcare worker training to improve HU adoption. The ACCELERATE study aims to evaluate the adoption of HU among providers through the Screen, Initiate, and Maintain (SIM) intervention, facilitated by healthcare worker training, clinical reminders, and task-sharing strategies, thereby enhancing patient-level SCD management in Nigeria.

Methods: This study will implement the SIM intervention, encompassing patient screening, initiation of HU treatment, and maintenance of dosage, which will be implemented via the TAsk-Strengthening Strategy for Hemoglobinopathies (TASSH TCP), derived from our team's TAsk-Strengthening Strategy for Hypertension control (TASSH) trials. Employing a sequential exploratory mixed-methods approach within the Exploration, Preparation, Implementation, and Sustainment (EPIS) framework, this study will assess SIM adoption by providers in Nigeria. The primary outcome is the rate of SIM adoption at clinical sites at 12 months, with secondary outcomes including sustainability/maintenance of SIM intervention and implementation fidelity.

Discussion: This study's findings will offer crucial insights into effective SCD management strategies, leveraging existing SCD clinical networks and resources in Nigeria to enhance HU adoption among providers in a scalable and sustainable manner. Additionally, the study will inform best practices for implementing HU therapy in resource-constrained settings, benefiting healthcare providers, policymakers, and stakeholders invested in improving SCD care delivery.

Trial registration: NCT06318143.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. ACCELERATE SPIRIT schedule.
*Note: Visit timepoints can range from monthly to every three months depending on patient needs. The above visit timepoints reflect the period of outcome data collection.
Fig 2
Fig 2
A. TASSH TCP Study designed aligned with EPIS framework. B. TASSH TCP intervention components and overall structure of implementation trial.
See this image and copyright information in PMC

References

    1. Adewoyin A.S., Management of sickle cell disease: a review for physician education in Nigeria (sub-saharan Africa). Anemia, 2015. 2015: p. 791498. doi: 10.1155/2015/791498 - DOI - PMC - PubMed
    1. Chakravorty S. and Williams T.N., Sickle cell disease: a neglected chronic disease of increasing global health importance. Arch Dis Child, 2015. 100(1): p. 48–53. doi: 10.1136/archdischild-2013-303773 - DOI - PMC - PubMed
    1. Piel F.B., et al.., Global burden of sickle cell anaemia in children under five, 2010–2050: modelling based on demographics, excess mortality, and interventions. PLoS Med, 2013. 10(7): p. e1001484. doi: 10.1371/journal.pmed.1001484 - DOI - PMC - PubMed
    1. Ohene-Frempong K., et al.., Screening newborns for sickle cell disease in Ghana. Pediatrics, 2008. 121(2): p. S120. - PubMed
    1. Brown B.J., et al.., Burden of health-care of carers of children with sickle cell disease in Nigeria. Health Soc Care Community, 2010. 18(3): p. 289–95. doi: 10.1111/j.1365-2524.2009.00903.x - DOI - PubMed

Publication types

Associated data